MaxCyte, Inc. ( MXCT) Stock. Should you Buy or Sell? $ 6.38
-0.10 (-1.59 %)
MaxCyte, Inc. Analysis
Updated on 10-09-2022| Symbol | MXCT |
| Price | $6.38 |
| Beta | 1.262 |
| Volume Avg. | $460.61 thousand |
| Market Cap | $628.14 M |
| 52 Week Range | $3.36 - $16.28 |
MaxCyte, Inc. opened the day at $6.38 which is -1.59 % on yesterday's close. MaxCyte, Inc. has a 52 week high of $16.28 and 52 week low of $3.36, which is a difference of $12.92. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $628.14 M and total net profit is $33894100 which means the company is trading at 18.53 times profit to market capitalization. Theoretically, if you were to buy MaxCyte, Inc. for $628.14 M, it would take 15 years to get your money back. MaxCyte, Inc. are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
MaxCyte, Inc. Stock Forecast - Is MaxCyte, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -32.547 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -0.479 |
Valuing MaxCyte, Inc.
| Price Book Value Ratio | 2.516 | Price To Book Ratio | 2.516 |
| Price To Sales Ratio | 15.598 | Price Earnings Ratio | -32.547 |
How liquid is MaxCyte, Inc.
| Current Ratio | 14.239 |
| Quick Ratio | 13.740 |
Debt
| Debt Ratio | 0.112 | Debt Equity Ratio | 0.127 |
| Long Term Debt To Capitalization | 0.052 | Total Debt To Capitalization | 0.053 |
Latest news about MaxCyte, Inc.
ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 4:40 p.m. Eastern Time.
MaxCyte Inc (AIM:MXCT) has again raised its full-year outlook as it continued to enjoy strong growth in the cell therapy market. Revenue came in at US$9.6mln for the second quarter of 2022, up 35% year-on-year, with the core business growing 45% and drug discovery up 4%.
MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Sean Menarguez - Director of Investor Relations Doug Doerfler - Founder, President & Chief Executive Officer Ron Holtz - Chief Financial Officer Conference Call Participants Max Masucci - Cowen Operator Good day, and thank you for standing by, and welcome to MaxCyte Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 6.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the second quarter of 2022 after the U.S. market close on Wednesday, August 10th, 2022. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
About MaxCyte, Inc.
Description :
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
